VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
INNV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
INNVInnovAge Holding Corp.
$8.91$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. INNV
  4. Financial Ratios

InnovAge Holding Corp. (INNV) Financial Ratios

Latest Ratios: P/E Ratio 135.8x · EV/EBITDA 12.4x · ROE -1.0%. (2019–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

INNV Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$1.2B$1.6B$500M$674M$1.0B$594M$2.9B——
Enterprise Value$1.2B$1.6B$537M$730M$1.1B$494M$2.8B——
P/E Ratio →135.82————————
P/S Ratio1.191.620.590.881.480.854.53——
P/B Ratio4.505.981.902.253.391.688.07——
P/FCF15.8331.9018.78——————
P/OCF18.6824.8515.20——21.74———

P/E links to full P/E history page with 30-year chart

INNV EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—1.610.630.961.560.714.34——
EV / EBITDA12.3818.27———51.9031.76——
EV / EBIT18.0824.10———————
EV / FCF—31.6920.17——————

INNV Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin20.9%20.9%68.5%17.3%14.7%19.4%25.4%24.9%23.8%
Operating Margin6.7%6.7%-3.5%-3.0%-7.2%-0.6%11.7%9.0%8.5%
Net Profit Margin-0.3%-0.3%-3.6%-2.8%-5.9%-0.9%-6.9%4.6%4.2%

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-1.0%-1.0%-10.8%-7.1%-12.4%-1.8%-18.9%27.8%24.0%
ROA-0.5%-0.5%-5.3%-3.8%-7.3%-1.2%-9.3%6.8%5.4%
ROIC17.8%17.8%-6.8%-4.9%-12.1%-1.3%25.1%17.9%13.8%
ROCE17.8%17.8%-7.1%-5.5%-11.4%-1.0%18.9%16.6%14.2%

INNV Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.320.320.380.380.380.240.232.022.39
Debt / EBITDA0.990.99———8.910.953.504.00
Net Debt / Equity—-0.040.140.190.19-0.28-0.340.961.64
Net Debt / EBITDA-0.13-0.13———-10.47-1.391.662.74
Debt / FCF—-0.221.39————3.2311.70
Interest Coverage15.5715.57-3.50-4.42-32.37-1.87-1.083.443.85

Net cash position: cash ($98M) exceeds total debt ($87M)

INNV Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio1.051.051.071.251.252.293.192.181.43
Quick Ratio1.051.051.071.251.252.293.192.181.43
Cash Ratio0.690.690.640.740.741.752.591.490.73
Asset Turnover—1.781.531.321.261.241.181.381.28
Inventory Turnover—————————
Days Sales Outstanding—16.8416.9724.5827.2822.2921.7430.9243.12

INNV Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield——————0.3%——
Payout Ratio————————339.7%

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield0.7%————————
FCF Yield6.3%3.1%5.3%——————
Buyback Yield0.0%0.0%1.5%0.0%0.0%0.0%2.7%——
Total Shareholder Yield0.0%0.0%1.5%0.0%0.0%0.0%3.0%——
Shares Outstanding—$136M$135M$136M$136M$136M$136M$133M$133M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Clinical labor cost pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q1)

Negative Earnings Make Multiples Unreliable

INNV trades at a trailing P/E of -40.77 and a forward EV/EBITDA of 51.76, which according to the supplied valuation data reflects depressed earnings rather than a meaningful earnings multiple, so pricing must be anchored to sales and book value instead.

With trailing earnings still negative, the P/E ratio carries no interpretive weight and should be excluded from relative comparisons. The forward EV/EBITDA of 51.76 implies the market is capitalizing a recovery in EBITDA that has not yet appeared in reported results, which suggests investors are pricing in a successful margin turnaround. The P/S of 1.43 and P/B of 4.62 are more informative here, and the P/B premium relative to a business with an accumulated deficit suggests the market is assigning value to the participant base and recurring capitated revenue rather than to tangible asset backing.

Margin Recovery Still Unproven Across Cycles

Gross margin has risen from 16.8% to 21.9% over the last ten quarters while operating margin swung from -6.0% to 7.6%, and based on the reported figures this improvement rests on only a few recent quarters.

The expansion in gross margin indicates a better spread between capitated revenue and medical cost, but the operating margin remains thin relative to the gross margin, implying that center-level and corporate overhead still absorb most of the gross profit gain. The net margin of 7.4% in the latest quarter is flattered relative to the 3.2% reported in the prior quarter, which suggests that single-period results may overstate sustainable earning power. Investors should monitor whether operating margin holds above 6% through a full fiscal cycle before treating the recovery as structural.

Returns Turning Positive From a Deficit Base

ROIC has moved from -2.7% in mid-2025 to 5.9% in the latest quarter and ROE from -4.6% to 7.0%, which according to reported figures indicates a shift from value destruction toward thin positive returns.

The reversal in ROIC and ROE appears driven primarily by improved operating margins rather than by any material gain in capital efficiency, since asset turnover has held near 0.37 to 0.47 throughout the period. Returns remain low in absolute terms and may not yet cover the company's cost of capital given its capital-intensive, site-based footprint. The trend is encouraging, but a sustained ROIC above 8 to 10 percent would be needed before the business could credibly be described as compounding returns.

Low Debt Ratios Mask Interest Coverage Volatility

Debt-to-equity has stayed between 0.29 and 0.41 across ten quarters, but interest coverage swung from -16.71 to 163.90, which according to the reported ratios reflects a denominator effect from small interest expense rather than a clear improvement in debt service capacity.

A debt-to-equity ratio below 0.41 indicates modest leverage relative to equity, and the company's balance sheet does not appear to face near-term refinancing pressure based on the supplied figures. However, interest coverage ratios of 163.90 and 18.57 in recent quarters are not comparable to the negative values earlier, because the underlying interest expense base is small and volatile. Investors should treat coverage as a weak signal and focus instead on operating cash flow against fixed center costs.

Current Ratio Near One Leaves Thin Buffer

The current ratio has ranged from 0.78 to 1.26 over ten quarters and stood at 1.16 in the latest quarter, which according to reported balance sheet figures provides only a narrow cushion against short-term obligations.

Because inventory is negligible for a services provider, the quick ratio equals the current ratio and offers no additional discrimination, so the relevant question is whether receivables and cash can cover near-term payables and accrued medical claims. A current ratio dipping below 1.0, as occurred in Q3 2025 and Q3 2026, would indicate that current liabilities exceeded current assets, which under stress could compress the company's ability to absorb IBNR true-ups or delayed capitated receivables. This thin buffer warrants close monitoring rather than an assumption of comfort.

Peer Multiples Obscure Capital Intensity Gap

Relative to ALHC and OSCR, INNV's ROE of 7.0% and net margin of 7.4% look competitive, but based on reported figures its P/B of 4.62 and EV/EBITDA of 51.76 suggest the market is paying for a turnaround that has not yet reached the peer group's return profile.

The most commonly misapplied lens for this business is price-to-book, because INNV's book value includes substantial goodwill of $142.0M and net PP&E of $184.0M, making a P/B premium appear rich even though the physical PACE center footprint is an operating necessity rather than surplus capital. Analysts should instead adjust for center-level contribution margin and participant-months per center, which isolate the operating economics of the site-based model from corporate overhead. Investors should monitor whether the valuation premium narrows as center utilization improves and returns move sustainably above cost of capital.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open INNV Terminal

INNV Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

INNV — Frequently Asked Questions

Quick answers to the most common questions about buying INNV stock.

What is InnovAge Holding Corp.'s P/E ratio?

InnovAge Holding Corp.'s current P/E ratio is 135.8x. This places it at the 50th percentile of its historical range.

What is InnovAge Holding Corp.'s EV/EBITDA?

InnovAge Holding Corp.'s current EV/EBITDA is 12.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.0x.

What is InnovAge Holding Corp.'s ROE?

InnovAge Holding Corp.'s return on equity (ROE) is -1.0%. The historical average is -0.0%.

Is INNV stock overvalued?

Based on historical data, InnovAge Holding Corp. is trading at a P/E of 135.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are InnovAge Holding Corp.'s profit margins?

InnovAge Holding Corp. has 20.9% gross margin and 6.7% operating margin.

How much debt does InnovAge Holding Corp. have?

InnovAge Holding Corp.'s Debt/EBITDA ratio is 1.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.